Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Vax in resectable NSCLC
NCT00298298Phase 2Terminated
- Sponsor
- AVAX Technologies, Inc.
- Start
- Jan 2006
- Primary completion
- Jan 2014
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous DNP-modified vaccine in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AVAX Technologies, Inc. Primary endpoints: Cell-mediated immunity to autologous tumor cells at 3 months and Safety at 1 year. Started Jan 2006; status: terminated.
02
Drugs
autologous DNP-modified vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00298298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298298.